Hereditary Angioedema Market, by Drug Class,
Distribution Channel, and Region - Global Trends
and Forecast till 2025
Hereditary angioedema (HAE) is a rare disorder related with the immune system. The life-
threatening condition is caused due to the lack of C1-esterase inhibitor (C1-INH) causing the
blood vessels to dilate. The symptoms of the disease include recurrent episodes of edema in
various body parts such as hands, feet, face and airways. HAE is classified into 3 types: Type I
HAE, Type II HAE and Type III HAE based on the reduction in its synthesis of inhibitor or the
formation of a dysfunctional protein. Although, the condition is hereditary, the absence of a
family history does not rule out the diagnosis of HAE, indicating that as many as 25% of HAE
cases result from a spontaneous mutation of the C1-inhibitor gene at conception.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/1292
The global hereditary angioedema market was valued at US$ 1,563.7 million in 2016 and is
expected to witness a robust CAGR of 9.1% over the forecast period (2017 - 2025).
Market Dynamics
The major factor driving growth of the hereditary angioedema market include intense R&D
initiatives by the manufacturers to treat the condition, increasing prevalence of hereditary
angioedema and the presence of promising drug pipeline. For instance, in 2017, Attune
Pharmaceuticals, revealed the successful study results the first preclinical data results for ATN-
249, a novel orally administered plasma kallikrein inhibitor for the treatment of Hereditary
Angioedema (HAE). Also, the approval of novel therapies by the regulatory agencies is expected
to be a factor augmenting market growth. For instance, in 2014, the FDA approved Ruconest
manufactured by Pharming Healthcare, a recombinant C1-esterase inhibitor for the treatment of
acute attacks in adult and adolescent patients with HAE. However, lack of awareness regarding
the diseases, inefficient diagnosis and high cost of drugs are the factors restraining hereditary
angioedema market growth.
Increasing prevalence and rising awareness of hereditary angioedema to augment market growth